The landscape of precision psychiatry is still in its nascent stage, with many emerging and legacy companies venturing into the industry with their respective molecular diagnostic portfolios exclusively designed for the assessment and diagnosis of psychotic conditions. Precision psychiatry tests are based on core molecular diagnostic techniques that help researchers and physicians to better identify genetic and protein biomarkers underlying psychotic conditions, including Alzheimer’s disease, Parkinson’s disease, and autism, among others. Though precision psychiatry is still emerging in the precision medicine ecosystem, several companies are exploring various avenues in terms of technologies for advancing precision clinical care. In addition, with the advancements in sequencing technologies in the recent past, the diagnosis of psychotic conditions is expected to become a standard practice in the forthcoming years for offering tailored therapeutics.

、1. Product Definition 

2. Market Scope 

3. Research Methodology 

4. Market Overview 

5. Market Dynamics 

6. Industry Insights 

7. Competitive Landscape 

8. Global Precision Psychiatry Market (by Product Type) 

9. Global Precision Psychiatry Market (by Biomarker Type) 

10. Global Precision Psychiatry Market (by Sample) 

11. Global Precision Psychiatry Market (by Technology)